-
Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has announced the publication of the Phase I clinical study results for its CTLA-4 antibody porustobart (HBM4003) in combination with Junshi Biosciences’ PD-1 inhibitor toripalimab. This combination is aimed at treating advanced…
-
Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has reported a decline in its financial performance for the first half of 2024. The company’s overall revenues have dropped by 42.2% year-on-year to RMB 168 million (USD 23.7 million), with profits…
-
Harbour BioMed Reclaims Rights to HBM7008 as Cullinan Therapeutics Cancels Licensing Deal
•
Harbour BioMed (HBM), a biopharmaceutical company with operations in the Netherlands, the United States, and Suzhou, China, has announced that its U.S. partner, Cullinan Therapeutics Inc., will be returning the rights to the pipeline molecule HBM7008. This move cancels the licensing agreement that was initially focused on the development and…
-
Harbour BioMed Resubmits Biological License Application for Batoclimab in China
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has announced the resubmission of a biological license application (BLA) to China’s National Medical Products Administration (NMPA) for its drug candidate batoclimab (HBM9161) for the treatment of generalized myasthenia gravis (gMG). Batoclimab…
-
Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with a global presence in Suzhou, China, Cambridge in the US, has announced its financial results for the full year of 2023. The company reported a significant leap in revenues, reaching USD 89.5 million, which marks an increase of 119.9% year-on-year (YOY). In…
-
Harbour BioMed Partners with Boostimmune to Develop Novel ADC Therapies
•
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the US, and the Netherlands, has announced an antibody drug conjugate (ADC) discovery cooperation agreement with South Korea-based ADC specialist Boostimmune, Inc. The financial details of the agreement have not been disclosed. As per the terms…
-
Harbour BioMed Gets FDA Green Light for Phase I Study of BsAb Targeting PD-L1 and CD40
•
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the US, and the Netherlands, has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I study. The study will assess the safety, tolerability, pharmacokinetics, and anti-tumor…
-
Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the Netherlands, the United States, and China, has entered into a partnership with China-based GeneQuantum Healthcare. The collaboration aims to integrate the core technology platforms and professional expertise of both companies to empower the early discovery…
-
Nona Biosciences Partners with Ingenia for Immunological Therapeutics Development
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company with operations in the Netherlands, the United States, and China, has formed a strategic partnership with Ingenia Therapeutics, a pre-clinical biotech with a presence in the United States and South Korea. The collaboration aims to…
-
Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona’s proprietary technology to enhance BeiGene’s research capabilities. Financial details of the agreement have not…
